{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T13:03:55Z","timestamp":1777640635357,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","issue":"4","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmic Res"],"published-print":{"date-parts":[[2017]]},"abstract":"<b><i>Objectives:<\/i><\/b> To analyse drug development for open-angle glaucoma during the last 20 years. <b><i>Methods:<\/i><\/b> Research was performed by referring to clinical trials registered at the International Clinical Trials Registry Platform (ICTRP). A search for the condition \u201copen-angle glaucoma\u201d with the intervention \u201cdrug\u201d was performed. We included trials registered from 01\/01\/1995 to 01\/01\/2015, only involving studies in phases 1, 2, and 3. Only studies resorting to novel treatment strategies (either novel drugs or yet-untested fixed associations of approved medication) were considered. <b><i>Results:<\/i><\/b> We recorded 158 studies for the condition of open-angle glaucoma with a drug-based intervention; 65 of the studies reported phase 2 trials and 74 reported phase 3 trials. Pharmaceutical companies were the primary sponsors of 95.3% of the trials. Most of the studies (66.5%, <i>n<\/i> = 105) involved a new drug, and the remainder (33.5%, <i>n<\/i> = 53) tested fixed drug associations. The bulk of the trials (<i>n<\/i> = 99, 62.7%) involved the use of prostaglandin analogues, either as a comparator or a study drug. In descending order of frequency, the studies conducted involved Rho-kinase inhibitors (<i>n<\/i> = 15), carbonic anhydrase inhibitors (<i>n<\/i> = 14), \u03b2-blockers (<i>n<\/i> = 7), angiostatic steroids (<i>n<\/i> = 6), \u03b1<sub>2<\/sub>-adrenergic agonists (<i>n<\/i> = 4), 5-HT<sub>2A<\/sub> receptor agonists (<i>n<\/i> = 4), and NMDA receptor antagonists (<i>n<\/i> = 2). A cyclin-dependent kinase inhibitor, an LIM-domain kinase 2 inhibitor, an A1 adenosine receptor agonist, catechin, macrolide, saffron, and seawater were each tested in 1 clinical trial. <b><i>Conclusion:<\/i><\/b> Research into the medical treatment of glaucoma indicates the use of prostaglandin analogues. However, there are a significant number of trials testing other drug classes, particularly Rho-kinase inhibitors. This new focus could lead to a potential increase in the number of therapeutical options for the management of glaucoma in the future.<\/jats:p>","DOI":"10.1159\/000453527","type":"journal-article","created":{"date-parts":[[2017,1,11]],"date-time":"2017-01-11T22:01:18Z","timestamp":1484172078000},"page":"201-207","source":"Crossref","is-referenced-by-count":14,"title":["Open-Angle Glaucoma: Drug Development Pipeline during the Last 20 Years (1995-2015)"],"prefix":"10.1159","volume":"57","author":[{"given":"Andr\u00e9","family":"Vicente","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Prud'homme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joana","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu\u00eds","family":"Abeg\u00e3o Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingeborg","family":"Stalmans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2017,1,12]]},"container-title":["Ophthalmic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/453527","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/453527","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/453527","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T17:01:55Z","timestamp":1745427715000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000453527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":0,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,4,18]]}},"URL":"https:\/\/doi.org\/10.1159\/000453527","archive":["Portico"],"relation":{},"ISSN":["0030-3747","1423-0259"],"issn-type":[{"value":"0030-3747","type":"print"},{"value":"1423-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}